STUDIO PHARMA
InactiveInactive since 02-05-2026; last annual accounts for fiscal year 2024.
Signals
This company filed its last 7 accounts on average 33 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, abbreviated schema
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 70, Activities of head offices; management consultancy activities, each year against the same schema; no band under 30 filings. Dashed line: the median.
- 2024 Net result +84% on 2023. The accounts now follow the abbreviated schema, last year the micro schema.
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | €215,184 | €298,132 | €317,931 | €368,451 | ▲ 15.9% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €29,135 | €34,164 | €32,403 | €33,784 | €21,958 | ▼ 35.0% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | €0 | - | - | - | - |
| Other operating charges640/8 | - | €3,937 | €4,764 | €4,201 | €5,513 | ▲ 31.2% |
| Gross operating margin9900 | €496,754 | €542,967 | €783,266 | €917,872 | €1.1m | ▲ 17.9% |
| Operating profit (loss)9901 | €285,724 | €289,681 | €447,967 | €561,956 | €686,637 | ▲ 22.2% |
| Financial income75/76B | - | €13,025 | €10,670 | €7,921 | €197,606 | ▲ 2,395% |
| Recurring financial income75 | €4,146 | €13,025 | €10,670 | €7,921 | €197,606 | ▲ 2,395% |
| Financial charges65/66B | - | €6,633 | €5,921 | €6,873 | €7,074 | ▲ 2.9% |
| Recurring financial charges65 | €4,955 | €6,633 | €5,921 | €6,873 | €7,074 | ▲ 2.9% |
| Profit (loss) for the period before taxes9903 | €284,915 | €296,073 | €452,716 | €563,004 | €877,170 | ▲ 55.8% |
| Income taxes67/77 | €83,751 | €89,567 | €145,208 | €184,526 | €182,556 | ▼ 1.1% |
| Profit (loss) for the period9904 | €201,164 | €206,506 | €307,508 | €378,479 | €694,614 | ▲ 83.5% |
| Transfer from tax-exempt reserves789 | - | - | €35,600 | €77,700 | €42,100 | ▼ 45.8% |
| Transfer to tax-exempt reserves689 | - | €42,100 | €42,100 | €42,100 | €42,100 | = |
| Profit (loss) for the period to be appropriated9905 | €159,064 | €164,406 | €301,008 | €414,079 | €694,614 | ▲ 67.7% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €1.2m | €1.3m | €1.5m | €1.8m | €918,815 | ▼ 47.6% |
| Fixed assets21/28 | €493,264 | €467,706 | €438,936 | €448,065 | €58,975 | ▼ 86.8% |
| Intangible fixed assets21 | €0 | - | - | - | - | - |
| Tangible fixed assets22/27 | €493,264 | €467,606 | €438,836 | €447,965 | €58,875 | ▼ 86.9% |
| Land and buildings22 | - | €411,022 | €394,777 | €378,532 | €0 | ▼ 100% |
| Plant, machinery and equipment23 | - | €643 | €473 | €303 | €2,092 | ▲ 591% |
| Furniture and vehicles24 | - | €11,082 | €10,244 | €44,480 | €42,004 | ▼ 5.6% |
| Other tangible fixed assets26 | - | €44,860 | €33,342 | €24,650 | €14,779 | ▼ 40.0% |
| Financial fixed assets28 | - | €100 | €100 | €100 | €100 | = |
| Current assets29/58 | €698,427 | €823,548 | €1.0m | €1.3m | €859,840 | ▼ 34.1% |
| Amounts receivable within one year40/41 | €96,796 | €147,078 | €169,655 | €240,477 | €197,737 | ▼ 17.8% |
| Trade receivables40 | - | €147,078 | €169,558 | €240,477 | €197,604 | ▼ 17.8% |
| Other amounts receivable41 | - | - | €97 | €0 | €133 | - |
| Current investments50/53 | €323,192 | €452,568 | €661,393 | €949,779 | €502,686 | ▼ 47.1% |
| Cash at bank and in hand54/58 | €274,234 | €220,308 | €214,951 | €109,011 | €146,676 | ▲ 34.6% |
| Deferred charges and accrued income490/1 | - | €3,594 | €3,985 | €5,826 | €12,742 | ▲ 119% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €1.2m | €1.3m | €1.5m | €1.8m | €918,815 | ▼ 47.6% |
| Equity10/15 | €701,356 | €827,407 | €1.0m | €1.3m | €814,971 | ▼ 37.3% |
| Contributions10/11 | - | €12,400 | €12,400 | €12,400 | €12,400 | = |
| Reserves13 | €688,956 | €815,007 | €989,085 | €1.3m | €802,571 | ▼ 37.6% |
| Tax-exempt reserves132 | - | €155,400 | €161,900 | €126,300 | €126,300 | = |
| Distributable reserves133 | - | €659,607 | €827,185 | €1.2m | €676,271 | ▼ 41.7% |
| Profit (loss) carried forward14 | - | €0 | €0 | €0 | €0 | - |
| Amounts payable17/49 | €490,335 | €463,847 | €487,435 | €453,974 | €103,845 | ▼ 77.1% |
| Amounts payable after more than one year17 | €365,212 | €340,299 | €315,087 | €289,572 | €0 | ▼ 100% |
| Financial debts170/4 | - | €340,299 | €315,087 | €289,572 | €0 | ▼ 100% |
| Amounts payable within one year42/48 | €123,745 | €122,347 | €171,448 | €163,202 | €103,845 | ▼ 36.4% |
| Current portion of amounts payable after more than one year42 | - | €24,913 | €25,212 | €25,515 | €0 | ▼ 100% |
| Trade debts44 | €5,074 | €30,884 | €28,649 | €41,567 | €28,988 | ▼ 30.3% |
| Suppliers440/4 | - | €30,884 | €28,649 | €41,567 | €28,988 | ▼ 30.3% |
| Taxes, remuneration and social security45 | - | €46,738 | €71,213 | €56,862 | €42,556 | ▼ 25.2% |
| Taxes450/3 | - | €21,804 | €41,754 | €29,355 | €7,714 | ▼ 73.7% |
| Remuneration and social security454/9 | - | €24,935 | €29,459 | €27,507 | €34,842 | ▲ 26.7% |
| Other amounts payable47/48 | - | €19,812 | €46,374 | €39,259 | €32,300 | ▼ 17.7% |
| Accrued charges and deferred income492/3 | - | €1,200 | €900 | €1,200 | €0 | ▼ 100% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €201,164 | €206,506 | €307,508 | €378,479 | €694,614 | ▲ 83.5% |
| + Depreciation and write-downs630 | €29,135 | €34,164 | €32,403 | €33,784 | €21,958 | ▼ 35.0% |
| Operating cash flow (approximation) | €230,299 | €240,670 | €339,910 | €412,262 | €716,572 | ▲ 73.8% |
| Investment in fixed assets (approximation) | - | -€8,606 | -€3,633 | -€42,912 | €367,131 | ▲ 956% |
| Change in cash | - | -€53,926 | -€5,357 | -€105,940 | €37,665 | ▲ 136% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
18-02
State Gazette act
RestructuringMerger · Accounting effect · Power of attorney5 facts ▸
- Board meeting, 15-01-2026
- Merger, sister merger by absorption
- Merger, sister merger by absorption
- Accounting effect, 01-01-2026
- Power of attorney, In2pharma NV
About the unread acts
Of the 4 Belgian State Gazette acts we know for this company, 1 has been read. The other 3 have not been read yet: what they contain is neither established nor disproved here.
Directors · office · real estate
1 parcel
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44055A1207/00F000 | Flanders | 2,628 m² | 1 · 206 m² | 9.9 m · 2 fl. |
Linked by address, not proof of ownership
Structure & network
Connections & network
No current directors or connected companies found in the register.
Acquisitions and mergers
1 transactionPublic money · subsidies and aid
Flemish government
2023 · 1 entry · 2,985 EUR awarded · 2,985 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2023 | 1 | 2,985 EUR | 2,985 EUR |
Similar companies · same sector, comparable size
Identification & contact
The company is no longer active; its Peppol card can remain until its access point withdraws it.
Register as of 28 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.